🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07314346
Recruiting Phase 1

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

NCT07314346 · tracked via the Priya Life Science USA tracker
Sponsor
Atea Pharmaceuticals, Inc.
Phase
Phase 1
Started
2025-01-07
Last updated
2026-07-16

Condition(s) studied

Healthy Volunteer Study

Investigational drug(s) / intervention(s)

Buprenorphine/Naloxone + BEM/RZR →Methadone +BEM/RZRAll Methadone trials (2) →All BEM/RZR trials (2) →

Buprenorphine/Naloxone + BEM/RZR: Day -5 to Day -1:buprenorphine/naloxone as individualized QD doses up to 24mg/6mg. Day 1 to Day 5:Individualized QD doses of buprenorphine/naloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine/naloxone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of buprenorphine/naloxone.

Methadone +BEM/RZR: Day -5 to Day -1:methadone individualized QD doses: 30-150mg. Day 1 to Day 5:Individualized QD does of methadone. Day 6 to Day 12:Individualized QD doses of methadone + BEM 550mg/RZR 180mg QD. Day 13 Individualized QD doses of methadone.

Study summary

Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug. * Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/ m2. * Willing to comply with the study requirements and to provide written informed consent. Exclusion Criteria: * Infected with hepatitis B virus, hepatitis C virus, HIV. * Abuse of alcohol or drugs. * Use of other investigational drugs within 28 days prior to Day -5. * Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine/naloxone as assigned maintenance therapy). * Other clinically significant medical conditions or laboratory abnormalities.

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Atea Study Site Hollywood Florida Recruiting
Atea Study Site Overland Park Kansas Recruiting
Atea Study Site Marlton New Jersey Recruiting

More Atea Pharmaceuticals, Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07314346 on ClinicalTrials.gov ↗ ← All trials in the USA